Des-Gamma-Carboxyprothrombin for Early Identification and Prognosis of Hepatocellular Carcinoma - A Case Control Study from Western Nepal |
Mittal, Ankush
(Biochemistry, Nepalese Army Institute of Health Sciences)
Gupta, Satrudhan Pd (Biochemistry, Nepalese Army Institute of Health Sciences) Sathian, Brijesh (Community Medicine, Manipal College of Medical Sciences) Sreedharan, Jayadevan (Research Division, Gulf Medical University) Poudel, Bibek (Biochemistry, Manipal College of Medical Sciences) Yadav, Shambhu Kumar (Biochemistry, Manipal College of Medical Sciences) Pandeya, Dipendra Raj (Biochemistry, Nepalese Army Institute of Health Sciences) |
1 | Saelee P, Chuensumran U, Wongkham S, et al (2012). Hypermethylation of suppressor of cytokine signaling 1 in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 13, 3489-93. DOI |
2 | Suzuki M, Shiraha H, Fujikawa T, et al (???). Desgammacarboxyprothrombin is a potential autologous growth factorfor hepatocellular carcinoma. J Biol Chem, 280, 6409-15. |
3 | Weitz IC, Liebman HA (1993). Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology, 18, 990-7. DOI ScienceOn |
4 | Xu J, Liu C, Zhou L, et al (2012). Distinctions between clinicopathological factors and prognosis of alphafetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62. DOI ScienceOn |
5 | Ye JZ, Miao ZG, Wu FX, et al (2012). Recurrence after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 13, 1771-7. DOI |
6 | Sell LS (1990). Cancer markers of the 1990s. Clin Lab Med, 10, 1-37. |
7 | El-Attar HA, Kandil MH, El-Kerm YM, et al (2010). Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev, 11, 897-903. |
8 | Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol , 45, 1272-82. DOI |
9 | Bertino G, Ardiri AM, Calvagno GS, et al (2010). Prognostic and diagnostic value of des--carboxy prothrombin in liver cancer. Drug News Perspect, 23, 498-508. |
10 | Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91. |
11 | Fujikawa T, Shiraha H, Yamamoto K (2009). Significance of desgamma-carboxyprothrombin production in hepatocellular carcinoma. Acta Med Okayama, 63, 299-304. |
12 | Fujiyama S, Izuno K, Gohshi K, et al (1991). Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci, 36, 1787-92. DOI ScienceOn |
13 | Mittal A, Sathian B, Chandrashekharan N, et al (2011). Diagnostic significance of alpha fetoprotein in carcinomas of liver and biliary tract -a comparative study from the western region of Nepal. Asian Pac J Cancer Prev, 12, 3475-8. |
14 | Okuda H, Nakanishi T, Takatsu K, et al (2002). Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol, 17, 772-8. DOI |